Stranded Technologies Podcast

<p>Ian Huyett is an attorney at Cornerstone in New Hampshire, where he leads litigation and policy work for a network of over one hundred churches. He helped design New Hampshire’s new Right to Try framework, which provides some of the strongest protections in the U.S. for patients seeking access to experimental treatments.</p><p><strong>Read the Essay: The Christian War on Death</strong><strong><em>How Christianity reframed mortality and unleashed biotech acceleration. </em></strong></p><p></p><p>In this episode, Ian and Niklas explore the alignment between serious Christian theology and biotech acceleration. Ian makes the case for combating sickness, aging, and death, challenges ideas like “death gives life meaning” or “playing God,” and explains why Christians have long driven medical innovation. The discussion then shifts to law and strategy, including the New Hampshire Right to Try bill, the role of civil liability, and how states like New Hampshire, Montana, and Florida are opening real paths for experimental treatments.</p><p></p><p><strong>More about Ian’s work:</strong></p><p>* <a target="_blank" href="https://x.com/nhcornerstone">Corner Stone Action</a></p><p>* <a target="_blank" href="https://x.com/IanHuyett">Ian’s X</a></p><p><strong>Explore Infinita City:</strong></p><p>* <a target="_blank" href="https://www.infinita.city/times">Explore the Archive: The Infinita City Times</a></p><p>* <a target="_blank" href="https://www.infinita.city">Visit Infinita City</a></p><p>* <a target="_blank" href="https://www.infinita.city/builders-hub">Join the Builders’ Hub on Telegram</a></p><p>* <a target="_blank" href="https://x.com/InfinitaCity">Follow Infinita City on X</a></p> <br/><br/>This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://www.infinitacitytimes.com?utm_medium=podcast&#38;utm_campaign=CTA_1">www.infinitacitytimes.com</a>

<p><strong>Arjun Khemani </strong>is one of the sharpest young thinkers in the progress movement.He dropped out of high school at 16, built apps with Naval’s team, ran a podcast with guests like David Deutsch and Balaji, and found himself inside the Bitcoin–Zcash privacy debate before turning 20.</p><p>Niklas sits down with Arjun to explore how COVID shifted his worldview, how <strong><em>The Beginning of Infinity</em></strong> pushed him toward a deeper model of progress, and why privacy became central to his thinking about innovation.</p><p>They unpack <a target="_blank" href="https://z.cash/"><strong>Zcash</strong></a> as an encrypted monetary system, how zero-knowledge proofs work in practice, how privacy shapes creativity and risk-taking, and what a modern Renaissance of talent could look like in a world built on cryptography.</p><p>They also cover:</p><p>* The path from Bitcoin to Zcash and the tech behind shielded transactions</p><p>* Privacy as a foundation for authenticity, safety, and experimentation</p><p>* AI-driven surveillance and its implications for money</p><p>* Funding talented people and the lessons from the Medici era</p><p>* The philosophical lineage: Deutsch, Popper, Schmer, optimism, error correction</p><p>* How Zcash fits into the broader landscape of crypto protocols</p><p>A conversation for anyone thinking about cryptography, progress, startup societies, and how the next wave of talent emerges and gets supported.</p><p></p><p></p><p><strong>More about Arjun’s work:</strong></p><p>* <a target="_blank" href="https://x.com/arjunkhemani">Arjun’s X</a></p><p>* <a target="_blank" href="https://www.arjunkhemani.com/">Substack/Podcast</a></p><p><strong>Explore Infinita City:</strong></p><p>* <a target="_blank" href="https://www.infinita.city/times">Explore the Archive: The Infinita City Times</a></p><p>* <a target="_blank" href="https://www.infinita.city">Visit Infinita City</a></p><p>* <a target="_blank" href="https://www.infinita.city/builders-hub">Join the Builders’ Hub on Telegram</a></p><p>* <a target="_blank" href="https://x.com/InfinitaCity">Follow Infinita City on X</a></p> <br/><br/>This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://www.infinitacitytimes.com?utm_medium=podcast&#38;utm_campaign=CTA_1">www.infinitacitytimes.com</a>

<p><strong>Ep. 101: Bryan Caplan: Pro Market & Pro Business, the Real Ethics of Entrepreneurship</strong></p><p>Bryan Caplan is a professor of economics at George Mason University and the author of several books, <a target="_blank" href="https://www.amazon.com/Open-Borders-Science-Ethics-Immigration/dp/1250316960/ref=sr_1_1?crid=2F0XMDU0OAMUK&#38;keywords=open+borders+the+science+and+ethics+of+immigration&#38;qid=1688399294&#38;sprefix=open+borders%2Caps%2C106&#38;sr=8-1">including Open Borders - The Science and Ethics of Immigration</a>, <a target="_blank" href="https://www.amazon.com/Case-against-Education-System-Waste/dp/0691196451/ref=sr_1_2?qid=1688399312&#38;refinements=p_27%3ABryan+Caplan&#38;s=books&#38;sr=1-2&#38;text=Bryan+Caplan">The Case Against Education</a> and the <a target="_blank" href="https://www.amazon.com/Myth-Rational-Voter-Democracies-Policies/dp/0691138737/ref=sr_1_4?qid=1688399327&#38;refinements=p_27%3ABryan+Caplan&#38;s=books&#38;sr=1-4&#38;text=Bryan+Caplan">Myth of the Rational Voter</a>.</p><p>Niklas sits down with Bryan to talk about his new books and why markets often work better than we give them credit for. They dig into how governments block progress in the name of safety, why antitrust usually backfires, and how “free” public services wipe out space for affordable alternatives. Bryan makes a compelling new case for free markets - even free market advocates have often been overly critical of business, and he comes up with a novel concept: there are things that sound good and bad, and things that are good and bad. Politics is promoting things that sound good but are bad - markets are promoting things that sound bad but are good.</p><p>They also cover:</p><p>* the Microsoft antitrust case and its real cost</p><p>* why poor countries suffer from too little big business</p><p>* entrepreneurship as real-world experimentation</p><p>A conversation for anyone building around regulation or trying to understand how progress really happens.</p><p></p><p><strong>More about GUEST’S work:</strong></p><p>* <a target="_blank" href="https://en.wikipedia.org/wiki/Bryan_Caplan">Bryan’s Wiki</a></p><p>* <a target="_blank" href="https://x.com/bryan_caplan">Bryan’s X</a></p><p><strong>Explore Infinita City:</strong></p><p>* <a target="_blank" href="https://www.infinita.city/times">Explore the Archive: The Infinita City Times</a></p><p>* <a target="_blank" href="https://www.infinita.city">Visit Infinita City</a></p><p>* <a target="_blank" href="https://www.infinita.city/builders-hub">Join the Builders’ Hub on Telegram</a></p><p>* <a target="_blank" href="https://x.com/InfinitaCity">Follow Infinita City on X</a></p> <br/><br/>This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://www.infinitacitytimes.com?utm_medium=podcast&#38;utm_campaign=CTA_1">www.infinitacitytimes.com</a>

<p>Niklas sits down with biomedical researcher and libertarian author Mary Ruwart (<em>Death by Regulation</em>) to dissect how decades of FDA rules derailed innovation, extended timelines from 4 to 14 years, and quietly reshaped the entire pharma industry, from discovery to delivery.</p><p>Together, they unpack:</p><p>* The pivotal moments: 1962’s Kefeuver-Harris amendments and 1992’s PDUFA and how they changed the game</p><p>* Why the system now favors chronic medication over simpler or even one-shot cures</p><p>* How off-label use and underground networks (like HIV buyers clubs) filled the gaps left by regulation</p><p>* What the rollback of “Chevron Deference” means and why this may be the biggest opening in decades</p><p>* How “statistical significance” became a misleading gold standard</p><p>* Why founders still building in the U.S. need to understand the incentives behind drug lag, suppression of short-term treatments, and the quiet cartelization of Big Pharma</p><p>* What it means to build around, beyond or outside the FDA: from Montana to Próspera</p><p></p><p><strong>More about Mary’s work:</strong></p><p>* <a target="_blank" href="https://x.com/MaryRuwart">Mary’s X</a></p><p>* <a target="_blank" href="https://es.wikipedia.org/wiki/Mary_Ruwart">Wiki</a></p><p>* <a target="_blank" href="https://www.amazon.com/stores/Mary-J.-Ruwart/author/B001KC8O7S?ref=ap_rdr&#38;isDramIntegrated=true&#38;shoppingPortalEnabled=true&#38;ccs_id=62588392-7afb-4487-b5cd-31044d771c86">Amazon Books</a></p><p><strong>Explore Infinita City:</strong></p><p>* <a target="_blank" href="https://www.infinita.city/times">Explore the Archive: The Infinita City Times</a></p><p>* <a target="_blank" href="https://www.infinita.city">Visit Infinita City</a></p><p>* <a target="_blank" href="https://www.infinita.city/builders-hub">Join the Builders’ Hub on Telegram</a></p><p>* <a target="_blank" href="https://x.com/InfinitaCity">Follow Infinita City on X</a></p> <br/><br/>This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://www.infinitacitytimes.com?utm_medium=podcast&#38;utm_campaign=CTA_1">www.infinitacitytimes.com</a>

<p>Cremieux went from arguing against the death penalty as a teenager to becoming one of the most influential voices dissecting science online. Now with 250k+ followers on X, he’s known for exposing p-hacking, outcome switching, and selection effects that skew research.</p><p>In this conversation with Niklas, here’s what they actually talk about: why effect sizes in journals rarely match FDA data, how gene therapy’s real bottleneck is delivery not targets, and why siRNA is the most underrated modality in biotech right now.</p><p><strong>What you’ll hear in this episode:</strong></p><p>* The heuristics he uses to spot bad research at a glance</p><p>* Why published effect sizes are often 2–3x inflated compared to FDA data</p><p>* Selection effects that quietly shape everything from education outcomes to clinical trials</p><p>* The real bottleneck in gene therapy (delivery, not targets) and why germline bans hold back obvious wins</p><p>* How pragmatic trials and IRB reform could finally fix a broken system</p><p>* Why measles might come back and the case for vaccine mandates for kids</p><p>* The truth about longevity research: most “breakthroughs” just stop early deaths, not extend the right tail</p><p>* China’s clinical trial engine vs the slow US system</p><p>* The modality he thinks is most underpriced today: siRNA</p><p>For builders in science who care more about getting it right than playing along.</p><p><strong>More about GUEST’S work:</strong></p><p>* <a target="_blank" href="https://x.com/cremieuxrecueil">Cremieux’s X</a></p><p><strong>Explore Infinita City:</strong></p><p>* <a target="_blank" href="https://www.infinita.city/times">Explore the Archive: The Infinita City Times</a></p><p>* <a target="_blank" href="https://www.infinita.city">Visit Infinita City</a></p><p>* <a target="_blank" href="https://www.infinita.city/builders-hub">Join the Builders’ Hub on Telegram</a></p><p>* <a target="_blank" href="https://x.com/InfinitaCity">Follow Infinita City on X</a></p> <br/><br/>This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://www.infinitacitytimes.com?utm_medium=podcast&#38;utm_campaign=CTA_1">www.infinitacitytimes.com</a>